Clinical Trial: Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07752979) titled 'Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities' on Aug. 04.

Brief Summary: Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight with weight-related comorbidities.

ABBV-295 is an investigational long-acting amylin analog being developed for chronic weight management. Participants are placed into multiple treatment groups with different dosi...